NEW YORK (GenomeWeb) - The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have opened a comment period for the revised evidence-based guideline, "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."
The revised guideline is designed to provide recommendations for pathologists, oncologists, and other cancer and molecular diagnostic laboratory professionals for state-of-the-art molecular testing of lung cancer. The revisions are based on evidence from a review of published experimental literature since 2013 and include the recommendations from an expert panel of leaders in the field, the associations said. In conjunction with revising the guideline, CAP, IASLC, and AMP said they will develop clinical tools and resources for pathologists and oncologists that summarize the findings and recommendations.
The comment period ends on Aug. 2, 2016.
Cancer Genetics said this week that it will offer Ventana's PD-L1 (SP142) assay as a complementary diagnostic for Roche's new metastatic urothelial cancer drug, called Tecentriq (atezolizumab), both of which were approved by the US Food and Drug Administration last month.
Cancer Genetics said that its lab "now offers all the companion and complementary PD-L1 diagnostic tests available on the market for delivering on immuno-oncology therapeutic selection."
Charles River Laboratories International has acquired Blue Stream Laboratories, a contract research organization with expertise in structural and functional protein characterization programs, and the development and validation of assays for current good manufacturing practice lot release and stability programs. Terms of the acquisition were not disclosed.
Enzo Biochem said this week that its stock has been included in the Russell 3000 Index, Russell 2000 Index, and Russell Global Index, as of the close of trade on June 24.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.